[1]朱道信,罗志环,陈少健,等.唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响[J].医学信息,2021,34(23):162-164.[doi:10.3969/j.issn.1006-1959.2021.23.049]
　ZHU Dao-xin,LUO Zhi-huan,CHEN Shao-jian,et al.Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis[J].Medical Information,2021,34(23):162-164.[doi:10.3969/j.issn.1006-1959.2021.23.049]
点击复制

唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
162-164
栏目:
药物与临床
出版日期:
2021-12-01

文章信息/Info

Title:
Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis
文章编号:
1006-1959（2021）23-0162-03
作者:
朱道信; 罗志环; 陈少健; 等
（赣州市人民医院运动医学科，江西 赣州 341000）
Author(s):
ZHU Dao-xin; LUO Zhi-huan; CHEN Shao-jian; et al.
(Department of Sports Medicine,Ganzhou People’s Hospital,Ganzhou 341000,Jiangxi,China)
关键词:
骨质疏松症; 骨化三醇; 唑来膦酸; 骨密度; 骨代谢
Keywords:
Osteoporosis; Calcitriol; Zoledronic acid; Bone density; Bone metabolism
分类号:
R580
DOI:
10.3969/j.issn.1006-1959.2021.23.049
文献标志码:
A
摘要:
目的 研究唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响。方法 选取2020年6月-2021年6月我院收治的82例骨质疏松症患者，依据随机数字表法分为对照组和观察组，每组41例。对照组给予骨化三醇治疗，观察组在对照组基础上联合唑来膦酸治疗，比较两组骨密度（腰椎、股骨颈、髋部）、骨代谢相关指标[血清骨钙素（BGP）、总1型前胶原氨基端延长肽（总P1NP）、β-胶原特殊序列（β-CTX）]、疼痛模拟视觉评分量表（VAS）及不良反应发生情况。结果 观察组腰椎、股骨颈、髋部骨密度高于对照组，差异有统计学意义（P＜0.05）；观察组BGP、总P1NP、β-CTX水平及VAS评分低于对照组，差异有统计学意义（P＜0.05）。两组不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论 唑来膦酸联合骨化三醇可增加骨质疏松症患者骨密度，下调骨代谢指标，改善疼痛症状，且不增加不良反应发生风险。
Abstract:
Objective To study the effect of zoledronic acid combined with calcitriol on bone mineral density and bone metabolism related indexes in patients with osteoporosis.Methods A total of 82 patients with osteoporosis admitted to our hospital from June 2020 to June 2021 were randomly divided into control group and observation group, with 41 cases in each group. The control group was treated with calcitriol, and the observation group was treated with zoledronic acid on the basis of the control group. The bone mineral density (lumbar spine, femoral neck, hip), bone metabolism-related indicators [serum osteocalcin (BGP), total N-terminal propeptide of type 1 procollagen (total P1NP), β-crosslaps (β-CTX)], pain simulation visual score (VAS) and adverse reactions were compared between the two groups.Results The bone mineral density of lumbar spine, femoral neck and hip in the observation group was higher than that in the control group, and the difference was statistically significant (P<0.05). BGP, total P1NP, β-CTX levels and VAS scores in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).Conclusion Zoledronic acid combined with calcitriol can increase bone mineral density in patients with osteoporosis, reduce bone metabolism indexes, improve pain symptoms, and do not increase the risk of adverse reactions.

参考文献/References:

[1]吴肖萍,廖君妃,梁东华,等.阿仑膦酸钠、骨化三醇联合阿托伐他汀治疗老年性骨质疏松伴高脂血症的临床观察[J].中国医学工程,2018,26(8):95-97.[2]薛青,张礼超,周奕.骨化三醇对比普通维生素D3治疗骨质疏松症的临床研究[J].广州医药,2019,50(4):62-65.[3]Lee WC,Guntur AR,Long F,et al.Energy Metabolism of the Osteoblast: Implications for Osteoporosis[J].Endocr Rev,2017,38(3):255-266.[4]周影,潘卫民,孙雯,等.唑来膦酸及云克治疗骨质疏松症的疗效对比研究[J].海南医学院学报,2020,26(16):1237-1241,1249.[5]刘颖,马凤云.阿仑膦酸钠及唑来膦酸治疗原发性骨质疏松症患者的临床疗效研究[J].河北医学,2016,22(1):25-29.[6]沈追孟.唑来膦酸对骨质疏松症的疗效及其对骨代谢指标的影响[J].中国生化药物杂志,2016,36(4):74-76.[7]程晓光,徐文坚,吴艳,等.骨质疏松的影像学与骨密度诊断专家共识[J].中国骨质疏松杂志,2020,26(9):1249-1256.[8]朴金龙,代彦丽,程团结,等.阿法骨化醇联合唑来膦酸治疗绝经后骨质疏松症的临床研究[J].现代药物与临床,2019,34(5):1468-1472.[9]陈岚,顾明君.伊班膦酸钠联合骨化三醇治疗老年骨质疏松症的临床研究[J].现代药物与临床,2019,34(4):1162-1166.[10]卢广民,周生艳,徐剡.降钙素联合骨化三醇胶丸对糖尿病合并骨质疏松症的影响[J].中国骨质疏松杂志,2019,25(1):103-106.[11]黄灿河.阿仑膦酸钠、阿法骨化三醇联合钙剂治疗老年性骨质疏松症的疗效分析[J].海峡药学,2018,30(12):132-133.[12]王斌,李晶.骨化三醇联合降钙素对T2DM伴骨质疏松症患者糖代谢、骨代谢指标的影响[J].临床医学研究与实践,2021,6(16):74-76.[13]戴蓉芳,冯月英,乔红梅,等.骨化三醇联合碳酸钙D3片治疗老年女性骨质疏松症效果观察[J].中华实用诊断与治疗杂志,2018,32(7):678-680.[14]王文婕,傅文贞,何进卫,等.阿仑膦酸钠与唑来膦酸治疗绝经后骨质疏松症疗效比较[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):445-449.[15]杨志新,杨磊,钱阳晶.唑来膦酸对骨质疏松患者骨痛、骨密度和血清骨代谢标志物的影响[J].解放军医药杂志,2017,29(4):85-88.[16]孔瑞娜,高洁,张菊,等.唑来膦酸对女性骨质疏松症的疗效及其对骨标志物的影响[J].中国骨质疏松杂志,2017,23(4):496-501.[17]郑博觉.唑来膦酸联合骨化三醇治疗绝经后骨质疏松症的疗效及对患者血清相关骨代谢标志物的影响[J].中国临床实用医学,2017,18(1):49-51.[18]余筱燕,叶一,汤珂珂,等.唑来膦酸联合骨化三醇治疗原发性骨质疏松症的疗效及对骨代谢、胰岛素样生长因子1和瘦素的影响[J].中国临床药学杂志,2020,29(3):161-164.[19]冼海庭,刘海亮,邹而标,等.阿法骨化醇联合唑来膦酸对骨质疏松症患者骨密度和血清骨代谢指标的影响[J].北方药学,2020,17(1):13-14.[20]楚明.骨化三醇联合阿仑膦酸钠治疗老年糖尿病骨质疏松症临床效果观察[J].北方药学,2016,13(1):47.[21]钟志鹏,黄静,陈秀珊,等.阿仑膦酸钠与骨化三醇对老年性骨质疏松症患者骨代谢指标的影响比较[J].云南医药,2021,42(1):33-34.[22]Strom O,Lauppe R,Ljunggren O,et al.Real-world effectiveness of osteoporosis treatment in the oldest old[J].Osteoporos Int,2020,31(8):1525-1533.[23]陈清河,曾维铨,黄少辉,等.碳酸钙D3、骨化三醇联合唑来膦酸对2型糖尿病合并原发性骨质疏松症患者骨密度和骨痛的影响[J].中国骨质疏松杂志,2020,26(2):202-204,226.

相似文献/References:

[1]汪钦生,邵 敏,姜 涛.绝经后妇女中骨质疏松患者血清钙磷、骨代谢指标与BMD的关系[J].医学信息,2019,32(04):1.[doi:10.3969/j.issn.1006-1959.2019.04.001]
　WANG Qin-sheng,SHAO Min,JIANG Tao.Relationship between Serum Calcium,Phosphorus and Bone Metabolism Markers and BMD in Postmenopausal Women with Osteoporosis[J].Medical Information,2019,32(23):1.[doi:10.3969/j.issn.1006-1959.2019.04.001]
[2]冯欢欢.骨质疏松症中医理论研究的文献计量学分析[J].医学信息,2022,35(16):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
　FENG Huan-huan.Bibliometric Analysis of TCM Theoretical Research on Osteoporosis[J].Medical Information,2022,35(23):28.[doi:10.3969/j.issn.1006-1959.2022.16.006]
[3]李 红,孔令泉,吴凯南.乳腺癌相关骨质疏松症的发病机制及防治[J].医学信息,2020,33(07):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
　LI Hong,KONG Ling-quan,WU Kai-nan.Pathogenesis and Prevention of Breast Cancer Associated Osteoporosis[J].Medical Information,2020,33(23):36.[doi:10.3969/j.issn.1006-1959.2020.07.012]
[4]刘 纳,李玉兰,许明芳,等.2型糖尿病临床期肾病与骨密度及骨代谢标记物的相关性研究[J].医学信息,2020,33(08):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
　LIU Na,LI Yu-lan,XU Ming-fang,et al.Study on the Relationship Between Bone Mineral Density and Bone Metabolism Markers in Stage IV Nephropathy of Type 2 Diabetes Mellitus[J].Medical Information,2020,33(23):70.[doi:10.3969/j.issn.1006-1959.2020.08.023]
[5]石耀武,陶宝琛,张宏蕾.西安地区骨质疏松症的影响因素及中医证型分布[J].医学信息,2020,33(11):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
　SHI Yao-wu,TAO Bao-chen,ZHANG Hong-lei.Influencing Factors of Osteoporosis in Xi’an and Distribution of TCM Syndromes[J].Medical Information,2020,33(23):136.[doi:10.3969/j.issn.1006-1959.2020.11.043]
[6]岳洪武,黄德清.骨康胶囊对老年骨质疏松性髋部骨折内固定患者术后恢复、骨代谢及骨密度的影响[J].医学信息,2021,34(24):73.[doi:10.3969/j.issn.1006-1959.2021.24.015]
　YUE Hong-wu,HUANG De-qing.Effects of Gukang Capsule on Postoperative Recovery, Bone Metabolism and Bone Mineral Density in Elderly Patients with Osteoporotic Hip Fracture[J].Medical Information,2021,34(23):73.[doi:10.3969/j.issn.1006-1959.2021.24.015]
[7]兰 凯,张光伟,刘树义,等.骨化三醇对糖尿病肾病大鼠尿液Smad1水平的影响[J].医学信息,2021,34(01):75.[doi:10.3969/j.issn.1006-1959.2021.01.020]
　LAN Kai,ZHANG Guang-wei,LIU Shu-yi,et al.Effect of Calcitriol on Urine Smad1 Level in Rats with Diabetic Nephropathy[J].Medical Information,2021,34(23):75.[doi:10.3969/j.issn.1006-1959.2021.01.020]
[8]张 宁,夏晓黎,王亚锋,等.慢性阻塞性肺疾病合并骨质疏松症危险因素的Meta分析[J].医学信息,2022,35(24):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
　ZHANG Ning,XIA Xiao-li,WANG Ya-feng,et al.Meta-analysis of Risk Factors for Chronic Obstructive Pulmonary Disease Complicated with Osteoporosis[J].Medical Information,2022,35(23):108.[doi:10.3969/j.issn.1006-1959.2022.24.020]
[9]米尔阿地力·麦麦提依明,阿卜杜萨拉木·亚克甫,沈志敏.骨质疏松对全膝关节置换术后康复的影响[J].医学信息,2021,34(09):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
　Mieradili·Maimaitiyiming,Abudusalamu·Yakepu,SHEN Zhi-min.Effect of Osteoporosis on Rehabilitation After Total Knee Arthroplasty[J].Medical Information,2021,34(23):99.[doi:10.3969/j.issn.1006-1959.2021.09.026]
[10]周奕良,毛国庆.基于网络药理学和分子对接技术探讨淫羊藿苷治疗骨质疏松症的作用机制[J].医学信息,2023,36(05):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]
　ZHOU Yi-liang,MAO Guo-qing.The Mechanism of Icariin in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking Technology[J].Medical Information,2023,36(23):29.[doi:10.3969/j.issn.1006-1959.2023.05.005]

更新日期/Last Update: 1900-01-01